Radiotherapy is curative for localized Hodgkin's disease,1,2and there is now general agreement that advanced Hodgkin's diseasecan be cured by chemotherapy. This opinion is bolstered by the20-year survival experience of the original group of patientstreated with combination chemotherapy at the National CancerInstitute (Figure 1) and by experience with other regimens (Table 1)2,3,4,5,6,7,8,9.
View larger version (13K): [in this window]
[in a new window]
Figure 1. Survival of 188 Patients with Hodgkin's Disease Treated with MOPP (Mechlorethamine, Vincristine, Procarbazine, and Prednisone).
Circles denote patients who relapsed, and vertical lines patients without a relapse. Reprinted from Longo et al.4 with the permission of the publisher.
View this table: [in this window]
[in a new window]
From the Memorial Sloan-Kettering Cancer Center, New York (V.T.D.), and the National Cancer Institute, Bethesda, Md. (S.M.H.).
Address reprint requests to Dr. DeVita at the Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.
References
Related Letters:
Hodgkin's Disease
Perez E. A., Rosenthal S. A., DeVita V. T., Hubbard S. M.
Extract |
Full Text
N Engl J Med 1993;
329:361-362, Jul 29, 1993.
Correspondence
This article has been cited by other articles:
Bredenfeld, H., Franklin, J., Nogova, L., Josting, A., Fries, S., Mailander, V., Oertel, J., Diehl, V., Engert, A.
(2004). Severe Pulmonary Toxicity in Patients With Advanced-Stage Hodgkin's Disease Treated With a Modified Bleomycin, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, and Gemcitabine (BEACOPP) Regimen Is Probably Related to the Combination of Gemcitabine and Bleomycin: A Report of the German Hodgkin's Lymphoma Study Group. JCO
22: 2424-2429
[Abstract][Full Text]
Montalban, C., Garcia, J. F., Abraira, V., Gonzalez-Camacho, L., Morente, M. M., Bello, J. L., Conde, E., Cruz, M. A., Garcia-Sanz, R., Garcia-Larana, J., Grande, C., Llanos, M., Martinez, R., Flores, E., Mendez, M., Ponderos, C., Rayon, C., Sanchez-Godoy, P., Zamora, J., Piris, M. A.
(2004). Influence of Biologic Markers on the Outcome of Hodgkin's Lymphoma: A Study by the Spanish Hodgkin's Lymphoma Study Group. JCO
22: 1664-1673
[Abstract][Full Text]
Baetz, T., Belch, A., Couban, S., Imrie, K., Yau, J., Myers, R., Ding, K., Paul, N., Shepherd, L., Iglesias, J., Meyer, R., Crump, M.
(2003). Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol
14: 1762-1767
[Abstract][Full Text]
Kiani, B., Magro, C. M., Ross, P. Jr
(2003). Endobronchial presentation of Hodgkin lymphoma: a review of the literature. Ann. Thorac. Surg.
76: 967-972
[Abstract][Full Text]
Schnell, R., Staak, O., Borchmann, P., Schwartz, C., Matthey, B., Hansen, H., Schindler, J., Ghetie, V., Vitetta, E. S., Diehl, V., Engert, A.
(2002). A Phase I Study with an Anti-CD30 Ricin A-Chain Immunotoxin (Ki-4.dgA) in Patients with Refractory CD30+ Hodgkin's and Non-Hodgkin's Lymphoma. Clin. Cancer Res.
8: 1779-1786
[Abstract][Full Text]
Tesch, H., Diehl, V., Lathan, B., Hasenclever, D., Sieber, M., Ruffer, U., Engert, A., Franklin, J., Pfreundschuh, M., Schalk, K.P., Schwieder, G., Wulf, G., Dolken, G., Worst, P., Koch, P., Schmitz, N., Bruntsch, U., Tirier, C., Muller, U., Loeffler, M.
(1998). Moderate Dose Escalation for Advanced Stage Hodgkin's Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Scheme and Adjuvant Radiotherapy: A Study of the German Hodgkin's Lymphoma Study Group. Blood
92: 4560-4567
[Abstract][Full Text]
Multani, P. S., Grossbard, M. L.
(1996). Staging Laparotomy in the Management of Hodgkin's Disease: Is it Still Necessary?. The Oncologist
1: 41-55
[Abstract][Full Text]
Perez, E. A., Rosenthal, S. A., DeVita, V. T., Hubbard, S. M.
(1993). Hodgkin's Disease. NEJM
329: 361-362
[Full Text]
Previous
